Ameriprise Financial Inc Homology Medicines, Inc. Transaction History

Ameriprise Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$6.02 - $9.64 $138,682 - $222,076	-23,037 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.17 - $14.8 $384,507 - $620,578	-41,931 Reduced 64.54%	23,037 $217,000
Q4 2020 Feb 12, 2021	SELL	$8.92 - $13.29 $14,994 - $22,340	-1,681 Reduced 2.52%	64,968 $733,000
Q3 2020 Nov 16, 2020	SELL	$9.94 - $16.59 $207,437 - $346,216	-20,869 Reduced 23.85%	66,649 $713,000
Q2 2020 Aug 14, 2020	SELL	$12.07 - $19.34 $354,882 - $568,634	-29,402 Reduced 25.15%	87,518 $1.33 Million
Q1 2020 May 15, 2020	BUY	$12.5 - $22.04 $135,837 - $239,508	10,867 Added 10.25%	116,920 $1.82 Million
Q4 2019 Feb 14, 2020	BUY	$11.42 - $22.19 $50,179 - $97,502	4,394 Added 4.32%	106,053 $2.2 Million
Q3 2019 Nov 14, 2019	BUY	$14.74 - $22.28 $94,247 - $142,458	6,394 Added 6.71%	101,659 $1.84 Million
Q2 2019 Aug 14, 2019	SELL	$18.35 - $30.34 $57,417 - $94,933	-3,129 Reduced 3.18%	95,265 $1.86 Million
Q1 2019 May 15, 2019	BUY	$19.76 - $29.57 $772,141 - $1.16 Million	39,076 Added 65.88%	98,394 $2.73 Million
Q4 2018 Feb 14, 2019	BUY	$18.39 - $26.3 $1.09 Million - $1.56 Million	59,318 New	59,318 $1.33 Million

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.